Skip to main content
. 2016 Aug 23;7(39):63629–63639. doi: 10.18632/oncotarget.11556

Figure 1. MYCN and PRMT1 correlations in neuroblastomas.

Figure 1

(A) Immunostaining for PRMT1 in neuroblastoma. (B) PRMT1 protein expression in ganglioneuroma (GN)/ganglioneuroblastoma (GNB) and neuroblastoma (NB) patients. **P < 0.01. (C) Bar graph shows case distribution of MYCN levels by PRMT1 levels. (D) Immunostaining for PRMT1 and MYCN in neuroblastoma. (E) Western blot of whole cell lysate from neuroblastoma cell lines with the indicated antibodies.